Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
RVTY delivered modest revenue growth of 3.7% to $2.86B in FY2025, but net income declined 10.8% to $241.2M as higher R&D spending, increased current liabilities, and aggressive share buybacks of $820.8M weighed on profitability and cash balances.
Revenue
$2.86B
+3.67% YoY
EPS (Diluted)
$2.07
-5.91% YoY
Operating Income
$356.63M
+2.85% YoY
Source: SEC XBRL
Revvity (RVTY) reported FY2025 revenue of $2.86B, up 3.7% year over year. Operating margin was 12.5%, down 0.1 points from 12.6% a year earlier. Operating cash flow was $582.93M, down 7.2% year over year.
Last 4 quarters: 4 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026 | 1.41 | 1.25 | Beat +13.1% |
| Mar 2026 | 1.06 | 1.04 | Beat +2.3% |
| Dec 2025This filing | 1.70 | 1.58 | Beat +7.4% |
| Sep 2025 | 1.18 | 1.16 | Beat +1.7% |
Reported EPS of $1.70 versus the $1.58 analyst consensus — a +7.4% beat for Dec 2025.
Compiled by AI from this SEC filing
RVTY grew total revenue by 3.7% year-over-year to $2.856B in FY2025 (from $2.755B in FY2024), suggesting steady demand for its life sciences and diagnostics products despite a challenging macro environment.
Source: 10-K Income Statement
Net income fell 10.8% to $241.2M from $270.4M in the prior year, indicating that revenue growth was more than offset by rising costs, including a 9.7% increase in R&D expense to $215.8M, compressing the net margin to 8.4%.
Source: 10-K Income Statement
RVTY more than doubled its share buybacks in FY2025, spending $820.8M compared to $369.6M in FY2024 — a 122.1% increase — which significantly reduced cash and equivalents by 20.9% to $919.9M and contributed to a 5.4% decline in stockholders' equity.
Source: 10-K Cash Flow Statement
Current liabilities more than doubled, rising 103.8% to $1.331B from $653.1M, which likely reflects reclassification of debt maturities or other near-term obligations coming due, warranting close monitoring of liquidity despite a current ratio of 1.68.
Source: 10-K Balance Sheet
Long-term debt declined 16.5% to $2.631B from $3.150B, suggesting RVTY made meaningful progress in deleveraging its balance sheet, with a debt-to-equity ratio of 0.68, which is manageable but still notable given the elevated current liabilities.
Source: 10-K Balance Sheet
Compiled by AI from this SEC filing · 2 high, 2 medium, 1 low
Current liabilities more than doubled to $1.331B in FY2025, likely due to near-term debt maturities being reclassified from long-term. While the current ratio of 1.68 remains above 1.0, cash declined 20.9% to $919.9M, leaving limited buffer if obligations accelerate or operating cash flow weakens further.
Source: 10-K Balance Sheet
Operating cash flow fell 7.2% to $582.9M in FY2025, even as revenue grew 3.7%, suggesting that working capital dynamics or non-cash adjustments are eroding cash generation quality. Sustained deterioration could limit RVTY's ability to fund buybacks, R&D, and debt repayment simultaneously.
Source: 10-K Cash Flow Statement
R&D expense increased 9.7% to $215.8M, growing nearly three times faster than revenue. If this investment does not translate into new product revenue in the near term, it will continue to pressure net margins, which already declined to 8.4% in FY2025.
Source: 10-K Income Statement
RVTY spent $820.8M on share repurchases in FY2025, more than 1.4x its operating cash flow of $582.9M, effectively funding buybacks through cash reserves and debt. This aggressive return of capital reduces financial flexibility and could constrain strategic investments or acquisitions.
Source: 10-K Cash Flow Statement
Total assets fell 1.8% to $12.17B and stockholders' equity declined 5.4% to $7.25B, reflecting the combined impact of buybacks and net income shortfalls. A shrinking equity base reduces ROE optically but also signals reduced book value support for the stock.
Source: 10-K Balance Sheet
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $B | 2.86 $B | 2.76 $B | +3.67% |
Operating Income $M | 356.64 $M | 346.74 $M | +2.85% |
Net Income $M | 241.20 $M | 270.39 $M | -10.79% |
EPS (Basic) $ | 2.07 $ | 2.21 $ | -6.33% |
EPS (Diluted) $ | 2.07 $ | 2.20 $ | -5.91% |
R&D Expense $M | 215.84 $M | 196.84 $M | +9.65% |
SG&A Expense $M | 991.89 $M | 994.07 $M | -0.22% |
Answers draw on this SEC filing and the data on this page
Revvity's Q2 FY2026 performance reflected a $16.2 million tariff refund that boosted gross margin, but higher restructuring costs and a decline in Life Sciences software revenue led to a 1.6% dip in operating income.
RVTY delivered 7.0% revenue growth to $711.1M in Q2 2026, but net income slipped 3.6% to $40.7M as cost of revenue rose faster than sales and cash balances declined 24.4% year-over-year.
Other companies in Health Care Equipment